Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information...
Cheers
Ulf
Olivier, the "work horse" ;) finally managed to get all the chapters back from the various authors and the book goes into print. Book should be available at Routledge in a couple of month.